Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

569495.pdf (225.81 KB)

Document type

Article

Version

Published version

Publication date

2009-08-05

Publication license

cc-by (c) Rubio Valera, Maria et al., 2009
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/44028

Community pharmacist intervention in depressed primary care patients (PRODEFAR study): randomized controlled trial protocol.

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

http://dx.doi.org/10.1186/1471-2458-9-284

Abstract

Background: Treatment of depression, the most prevalent and costly mental disorder, needs to be improved. Non-concordance with clinical guidelines and non-adherence can limit the efficacy of pharmacological treatment of depression. Through pharmaceutical care, pharmacists can improve patients' compliance and wellbeing. The aim of this study is to evaluate the effectiveness and costeffectiveness of a community pharmacist intervention developed to improve adherence and outcomes of primary care patients with depression. Methods/design: A randomized controlled trial, with 6-month follow-up, comparing patients receiving a pharmaceutical care support programme in primary care with patients receiving usual care. The total sample comprises 194 patients (aged between 18 and 75) diagnosed with depressive disorder in a primary care health centre in the province of Barcelona (Spain). Subjects will be asked for written informed consent in order to participate in the study. Diagnosis will be confirmed using the SCID-I. The intervention consists of an educational programme focused on improving knowledge about medication, making patients aware of the importance of compliance, reducing stigma, reassuring patients about side-effects and stressing the importance of carrying out general practitioners' advice. Measurements will take place at baseline, and after 3 and 6 months. Main outcome measure is compliance with antidepressants. Secondary outcomes include; clinical severity of depression (PHQ-9), anxiety (STAI-S), health-related quality of life (EuroQol-5D), satisfaction with the treatment received, side-effects, chronic physical conditions and sociodemographics. The use of healthcare and social care services will be assessed with an adapted version of the Client Service Receipt Inventory (CSRI). Discussion: This trial will provide valuable information for health professionals and policy makers on the effectiveness and cost-effectiveness of a pharmaceutical intervention programme in the context of primary care. Trial registration: NCT00794196

Subject

Atenció farmacèutica, Atenció primària, Depressió psíquica, Anàlisi cost-benefici, Assaigs clínics

Subject (English)

Pharmacy practice, Primary health care, Mental depression, Cost effectiveness, Clinical trials

Citation

Collections

Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
Articles publicats en revistes (Bioquímica i Fisiologia)

Citation

RUBIO VALERA, Maria, et al. Community pharmacist intervention in depressed primary care patients (PRODEFAR study): randomized controlled trial protocol. Bmc Public Health. 2009. Vol. 9, num. 284. ISSN 1471-2458. [consulted: 13 of August of 2026]. Available at: https://hdl.handle.net/2445/44028

Export metadata

JSON - METS

Share record